4ype Citations

Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.

Biochemistry 54 5401-13 (2015)
Related entries: 4ynm, 4ynp, 4ypa, 4ypu

Cited: 14 times
EuropePMC logo PMID: 26292256

Abstract

ASH1L (absent, small, or homeotic-like 1) is a histone methyltransferase (HMTase) involved in gene activation that is overexpressed in multiple forms of cancer. Previous studies of ASH1L's catalytic SET domain identified an autoinhibitory loop that blocks access of histone substrate to the enzyme active site. Here, we used both nuclear magnetic resonance and X-ray crystallography to identify conformational dynamics in the ASH1L autoinhibitory loop. Using site-directed mutagenesis, we found that point mutations in the autoinhibitory loop that perturb the structure of the SET domain result in decreased enzyme activity, indicating that the autoinhibitory loop is not a simple gate to the active site but is rather a key feature critical to ASH1L function. We also identified a second loop in the SET-I subdomain of ASH1L that experiences conformational dynamics, and we trapped two different conformations of this loop using crystallographic studies. Mutation of the SET-I loop led to a large decrease in ASH1L enzymatic activity in addition to a significant conformational change in the SET-I loop, demonstrating the importance of the structure and dynamics of the SET-I loop to ASH1L function. Furthermore, we found that three C-terminal chromatin-interacting domains greatly enhance ASH1L enzymatic activity and that ASH1L requires native nucleosome substrate for robust activity. Our study illuminates the role of concerted conformational dynamics in ASH1L function and identifies structural features important for ASH1L enzymatic activity.

Articles - 4ype mentioned but not cited (1)

  1. Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase. Rogawski DS, Ndoj J, Cho HJ, Maillard I, Grembecka J, Cierpicki T. Biochemistry 54 5401-5413 (2015)


Reviews citing this publication (4)

  1. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. Rogawski DS, Grembecka J, Cierpicki T. Future Med Chem 8 1589-1607 (2016)
  2. Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics. Wang MY, Liow P, Guzman MIT, Qi J. ACS Chem Biol 17 744-755 (2022)
  3. Structure, Activity, and Function of SETMAR Protein Lysine Methyltransferase. Tellier M. Life (Basel) 11 1342 (2021)
  4. Recent advances in developing degraders & inhibitors of lysine methyltransferases. Velez J, Kaniskan HÜ, Jin J. Curr Opin Chem Biol 76 102356 (2023)

Articles citing this publication (9)

  1. Mrg15 stimulates Ash1 H3K36 methyltransferase activity and facilitates Ash1 Trithorax group protein function in Drosophila. Huang C, Yang F, Zhang Z, Zhang J, Cai G, Li L, Zheng Y, Chen S, Xi R, Zhu B. Nat Commun 8 1649 (2017)
  2. Covalent inhibition of NSD1 histone methyltransferase. Huang H, Howard CA, Zari S, Cho HJ, Shukla S, Li H, Ndoj J, González-Alonso P, Nikolaidis C, Abbott J, Rogawski DS, Potopnyk MA, Kempinska K, Miao H, Purohit T, Henderson A, Mapp A, Sulis ML, Ferrando A, Grembecka J, Cierpicki T. Nat Chem Biol 16 1403-1410 (2020)
  3. Human SETMAR is a DNA sequence-specific histone-methylase with a broad effect on the transcriptome. Tellier M, Chalmers R. Nucleic Acids Res 47 122-133 (2019)
  4. The molecular genetic make-up of male breast cancer. Moelans CB, de Ligt J, van der Groep P, Prins P, Besselink NJM, Hoogstraat M, Ter Hoeve ND, Lacle MM, Kornegoor R, van der Pol CC, de Leng WWJ, Barbé E, van der Vegt B, Martens J, Bult P, Smit VTHBM, Koudijs MJ, Nijman IJ, Voest EE, Selenica P, Weigelt B, Reis-Filho JS, van der Wall E, Cuppen E, van Diest PJ. Endocr Relat Cancer 26 779-794 (2019)
  5. Dynamic behavior of the post-SET loop region of NSD1: Implications for histone binding and drug development. Graham SE, Tweedy SE, Carlson HA. Protein Sci 25 1021-1029 (2016)
  6. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Nat Commun 12 2792 (2021)
  7. Identification of a peptide inhibitor for the histone methyltransferase WHSC1. Morrison MJ, Boriack-Sjodin PA, Swinger KK, Wigle TJ, Sadalge D, Kuntz KW, Scott MP, Janzen WP, Chesworth R, Duncan KW, Harvey DM, Lampe JW, Mitchell LH, Copeland RA. PLoS One 13 e0197082 (2018)
  8. Effect of H2A.Z deletion is rescued by compensatory mutations in Fusarium graminearum. Chen Z, Zehraoui E, Atanasoff-Kardjalieff AK, Strauss J, Studt L, Ponts N. PLoS Genet 16 e1009125 (2020)
  9. A loss-of-function variant in SUV39H2 identified in autism-spectrum disorder causes altered H3K9 trimethylation and dysregulation of protocadherin β-cluster genes in the developing brain. Balan S, Iwayama Y, Ohnishi T, Fukuda M, Shirai A, Yamada A, Weirich S, Schuhmacher MK, Dileep KV, Endo T, Hisano Y, Kotoshiba K, Toyota T, Otowa T, Kuwabara H, Tochigi M, Watanabe A, Ohba H, Maekawa M, Toyoshima M, Sasaki T, Nakamura K, Tsujii M, Matsuzaki H, Zhang KYJ, Jeltsch A, Shinkai Y, Yoshikawa T. Mol Psychiatry 26 7550-7559 (2021)